|
Re: Reports of Exempt Distribution
|
1
|
Zenith Epigenetics
|
Feb 06, 2023 11:59AM
|
|
Re: zenith trials
|
|
Zenith Epigenetics
|
Dec 09, 2022 11:28PM
|
|
Re: Illiquid
|
6
|
Resverlogix Corp.
|
Dec 08, 2022 10:23PM
|
|
Illiquid
|
2
|
Resverlogix Corp.
|
Dec 08, 2022 08:07PM
|
|
USA ZHCLF investors
|
6
|
Zenith Epigenetics
|
Oct 28, 2022 09:26PM
|
|
Re: ZHCLF
|
4
|
Zenith Epigenetics
|
Jul 26, 2022 01:18PM
|
|
PAH
|
7
|
Resverlogix Corp.
|
Jul 11, 2022 08:55PM
|
|
Re: COVID 19 / varients
|
10
|
Resverlogix Corp.
|
Apr 11, 2022 04:07PM
|
|
Re: RVX- Exempt Distribution
|
4
|
Resverlogix Corp.
|
Apr 01, 2022 06:37PM
|
|
Re: Drugmakers, scientists begin the hunt for long COVID treatments
|
8
|
Resverlogix Corp.
|
Mar 26, 2022 08:57PM
|
|
Re: Article in National Post Feb 11
|
4
|
Resverlogix Corp.
|
Feb 12, 2022 04:01PM
|
|
50% chance. ??
|
2
|
Resverlogix Corp.
|
Feb 11, 2022 11:59PM
|
|
Re: Momentum Players and Agoracom.com’s Rules
|
7
|
Resverlogix Corp.
|
Dec 20, 2021 09:51PM
|
|
Re: Update
|
8
|
Resverlogix Corp.
|
Dec 17, 2021 09:00PM
|
|
Re: Update
|
3
|
Resverlogix Corp.
|
Dec 16, 2021 05:16PM
|
|
Morocco compared to Saudi
|
2
|
Resverlogix Corp.
|
Nov 02, 2021 08:45PM
|
|
Re: Presentation
|
1
|
Resverlogix Corp.
|
Oct 05, 2021 03:30PM
|
|
Re: Resverlogix Announces Apabetalone Meets Primary Endpoint in a Pulmonary Arterial Hypertension Pilot Study
|
1
|
Resverlogix Corp.
|
Sep 08, 2021 07:54PM
|
|
Re: Resverlogix Announces Apabetalone Meets Primary Endpoint in a Pulmonary Arterial Hypertension Pilot Study
|
1
|
Resverlogix Corp.
|
Sep 08, 2021 06:55PM
|
|
Re: Zenith Shareholders
|
|
Zenith Epigenetics
|
Sep 02, 2021 12:01PM
|
